June 16, 2011
The Governor’s Council on Innovation and Technology (GCIT) was established in 2003 to act as a catalyst to develop new economic strategies. The Council provides a forum for ideas, as well as a framework, to enable Arizona to become a global leader in innovation and technology research, development and product creation.
June 16, 2011
The fundamental progress of Arizona’s Bioscience Roadmap has been captured since the beginning of 2003, when the 10-year plan’s implementation began. To gain a “30,000-foot view” of progress thusfar, read or download the annually produced brochures catalogued below. Further detail is provided in each of the quarterly updates. Read More
June 16, 2011
The Arizona BioIndustry Association, the unified voice of Arizona’s growing bioscience industry, today announced the hiring of Joan Koerber-Walker who joins the state-wide organization as President and CEO of AZBio effective immediately. Read More
June 16, 2011
A new economic impact study shows biotechnology, life sciences and medical research contribute billions of dollars in direct revenue to Oregon’s economy, and local biotech workers earn higher wages. Read More
June 15, 2011
June 15, 2011 Washington State University Spokane, WA Read More
June 15, 2011
This section contains the department’s rules for the endorsing practitioner therapeutic interchange program (TIP). TIP is established under RCW. The statutes require state-operated prescription drug programs to allow physicians and other prescribers to endorse a Washington preferred drug list (PDL) and, in most cases, requires pharmacists to automatically substitute a preferred, equivalent drug from the […]
May 20, 2011
By Jorgo Chatzimarkakis, PhD, member of European Parliament The Health Care Blog Around the world and now in the United States, there is a broadening discussion of how best to proceed down the path of approving and getting to market medicines called biosimilars. Biosimilars are non-identical copies of next generation medicines known as biologics. As […]
May 19, 2011
By Andre Williams, Association of Black Cardiologists Politic365.com President Barack Obama recently indicated his interest in improving the Food and Drug Administration’s (FDA) approval process for new medical devices, saying the agency could “keep patients safer while getting innovative and life-saving products to market faster.” Read More
May 10, 2011
Drugmakers seeking U.S. approval for the first lower-cost copies of biologic medicines made from living cells should initially pay application fees similar to charges for brand-name medicines, regulators said. Read More
